Comparative effectiveness from a single-arm trial and real-world data: alectinib versus ceritinib.
J Comp Eff Res
; 7(9): 855-865, 2018 09.
Article
em En
| MEDLINE
| ID: mdl-29944008
ABSTRACT
AIM:
To compare the overall survival of anaplastic lymphoma kinase-positive non-small-cell lung cancer patients who received alectinib with those who received ceritinib. MATERIALS &METHODS:
Two treatment arms (alectinib [n = 183] and ceritinib [n = 67]) were extracted from clinical trials and an electronic health record database, respectively. Propensity scores were applied to balance baseline characteristics. Kaplan-Meier and multivariate Cox regression were conducted.RESULTS:
After propensity score adjustment, baseline characteristics were balanced. Alectinib had a prolonged median overall survival (alectinib = 24.3 months and ceritinib = 15.6 months) and lower risk of death (hazard ratio 0.65; 95% CI 0.48-0.88).CONCLUSION:
Alectinib was associated with prolonged overall survival versus ceritinib, which is consistent with efficacy evidence from clinical trials.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Piperidinas
/
Pirimidinas
/
Sulfonas
/
Carbazóis
/
Carcinoma Pulmonar de Células não Pequenas
/
Inibidores de Proteínas Quinases
/
Neoplasias Pulmonares
/
Antineoplásicos
Limite:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
J Comp Eff Res
Ano de publicação:
2018
Tipo de documento:
Article
País de afiliação:
Reino Unido